Xinrong Tao

TL;DR: Inactivated Mers-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS- coV infection that is similar to that found with inactivated SARS-Cov vaccines from SARS -CoV infection.

TL;DR: It is shown that transgenic mice globally expressing hCD26/DPP4 were fully permissive to MERS-CoV infection, resulting in relentless weight loss and death within days postinfection, and this new and unique transgenic mouse model will be useful for furthering knowledge of MERS pathogenesis and for the development of vaccine and treatments against MSPV.

TL;DR: It is shown that a recombinant protein containing a 212-amino acid fragment in the truncated receptor-binding domain (RBD: residues 367–606) of MERS-CoV spike (S) protein fused with human IgG Fc fragment (S377-588-Fc) shows promise for further development as an effective and safe vaccine for the prevention of MORS infection.

TL;DR: A neutralizing monoclonal antibody, designated Mersmab1, is developed, which potently blocks MERS-CoV entry into human cells and can also serve as a useful tool to guide the design of effective MSPV vaccines.

TL;DR: The potential of developing MERS-CoV RBD protein into an effective and safe mucosal candidate vaccine for prevention of respiratory tract infections caused by MERS -CoV is suggested.